Orforglipron: a new GLP-1 receptor agonist in the dm+d The NHS Business Services Authority has added orforglipron to the dm+d dictionary (version 8.4.0). Orforglipron is a GLP-1 receptor agonist — a class of injectable medication used to improve blood glucose control in type 2 diabetes. What is orforglipron used for? Orforglipron is prescribed to improve […]
Nipocalimab added to NHS dm+d 8.4.0 — event medicine guidance
Nipocalimab: a new entry in the dm+d dictionary The NHS Business Services Authority has added nipocalimab to the dm+d dictionary (version 8.4.0). Nipocalimab is a neonatal Fc receptor (FcRn) antagonist — a specialist immunomodulator used to treat myasthenia gravis in patients with specific antibody profiles. What is nipocalimab used for? Nipocalimab is indicated for myasthenia […]
Brensocatib added to NHS dm+d 8.0.0 — what event medics need to know
Brensocatib: a new entry in the dm+d The NHS Business Services Authority has added brensocatib to the dm+d dictionary (version 8.0.0). Brensocatib is a dipeptidyl peptidase I (DPP-I) inhibitor — a selective enzyme inhibitor used in the management of chronic bronchiectasis. What is brensocatib used for? Brensocatib is indicated to reduce airway infections and exacerbations […]
Rhodiola rosea added to NHS dm+d 7.1.0 — what event medics need to know
Rhodiola rosea: a new entry in the dm+d dictionary The NHS Business Services Authority (NHS BSA) has added Rhodiola rosea to the dm+d dictionary (version 7.1.0). Rhodiola rosea is a herbal adaptogen — an unlicensed botanical product — used traditionally to reduce fatigue and support stress resilience. It is not a licensed medicine in the […]
Pelargonium sidoides added to NHS dm+d 7.1.0 — event medicine guidance
Pelargonium sidoides: a new herbal entry in dm+d The NHS Business Services Authority has added Pelargonium sidoides to the dm+d dictionary (version 7.1.0). This herbal extract, derived from the South African geranium plant, is used to support respiratory health — particularly in acute bronchitis and cough. Event medics and clinical teams should understand its role, […]
Deuruxolitinib added to NHS dm+d 6.1.0 — what you need to know
Deuruxolitinib: a new entry in the dm+d dictionary The NHS Business Services Authority has added deuruxolitinib to the dm+d (Dictionary of Medicines and Devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of targeted immunosuppressive agents increasingly used in dermatology and rheumatology. What is deuruxolitinib used for? Deuruxolitinib is […]
Clesrovimab added to NHS dm+d 6.1.0 — RSV passive immunisation for high-risk infants
Clesrovimab: a new monoclonal antibody in the dm+d The NHS Business Services Authority has added clesrovimab to the dm+d dictionary (version 6.1.0). Clesrovimab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F protein, used for passive immunisation in high-risk infants during RSV season. What is clesrovimab used for? Clesrovimab provides season-long protection […]
Deuruxolitinib added to NHS dm+d 6.1.0 — what you need to know
Deuruxolitinib: a new entry in the dm+d dictionary The NHS Business Services Authority (NHS BSA) has added deuruxolitinib to the dm+d (dictionary of medicines and devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of immunomodulatory agents used in dermatology and rheumatology. What is deuruxolitinib used for? Deuruxolitinib is […]
Clesrovimab added to NHS dm+d 6.1.0 — RSV protection for high-risk infants
Clesrovimab: a new monoclonal antibody in the dm+d The NHS Business Services Authority has added clesrovimab to the dm+d dictionary (version 6.1.0). Clesrovimab is a monoclonal antibody that targets the respiratory syncytial virus (RSV) F protein, used for passive immunisation in high-risk infants during RSV season. What is clesrovimab used for? Clesrovimab provides season-long protection […]
Deuruxolitinib added to NHS dm+d 6.1.0 — key information for event medics
Deuruxolitinib: a new entry in the dm+d dictionary The NHS Business Services Authority has added deuruxolitinib to the dm+d (dictionary of medicines and devices) in version 6.1.0. Deuruxolitinib is a selective Janus kinase (JAK) inhibitor — a class of targeted immunosuppressant drugs. What is it used for? Deuruxolitinib is indicated for the treatment of atopic […]